Another L.A. County city using automated cameras to ticket bus lane violations
Camera-powered ticketing systems for bus lane violations are now in effect for another Los Angeles County bus system.
On Monday, Culver City officially launched its Automated Bus Lane and Bus Stop Enforcement (ABLE) Program, which uses bus-mounted automated enforcement technology to ticket drivers who block or illegally park in bus lanes, in front of bus stops or along shared bike lanes.
'These illegal parking violations impact the safety, accessibility, and efficiency of public transit—particularly for riders with disabilities—by preventing buses from safely pulling to the curb and forcing passengers to board in unsafe areas,' Culver City officials wrote in a news release.
The cameras are in use on Culver CityBus vehicles, which operate seven lines and encompass 33 square miles in Culver City and surrounding communities.
The cameras collect evidence of a violation which is later reviewed manually by a human employee. Once confirmed that a parking violation has occurred, a ticket is then mailed to the vehicle's owner.
AI cameras ticket thousands for bus lane violations in L.A.
A 60-day warning period has come to an end, meaning vehicles will start receiving citations this week. First time offenders can expect to receive a $293 citation for blocking or illegally parking in these designated spots; low-income plans are available to residents.
The parking restrictions are not new, but were previously only enforced when a traffic officer was on the scene. Culver CityBus joins LA Metro in administering parking tickets using camera mounted on its buses.
Other major cities, including Oakland and Sacramento in California, and New York City, have used similar systems with proven track records, of success, Culver City officials said.
In New York, since 2019 when camera enforcement began, bus speeds have increased by as much as 36% in certain high-traffic areas, and collisions along bus routes with the technology decreased by as much as 34%, officials said.
For additional information about Culver CityBus and the ABLE Program, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
12 minutes ago
- Bloomberg
Nomura Flags Risk of Sharp Yen Rally on US-Japan Policy Pressure
Japanese investors pivoting out of US assets as yen yields rise — combined with implicit pressure from Washington over the exchange rate during trade talks — could push the currency about 6% higher against the dollar in the coming months, according to Nomura Holdings, Inc. The investment bank, among Japan's largest, now recommends shorting the greenback versus the yen, targeting a move in the pair to ¥136 by the end of September, from around ¥145 currently. Nomura's Yusuke Miyairi, Yujiro Goto and Dominic Bunning expect that the Bank of Japan 's steady pace of rate hikes, will 'encourage domestic investors to increase more domestic bond than overseas bond exposure,' they wrote in a Friday report to clients.
Yahoo
an hour ago
- Yahoo
JOB ALERT: Goodwill Industries of East Texas needs a WAT Trainer
Goodwill Industries of East Texas Tyler WAT Trainer Pay: $15 – $18 an hour – Full-time The incumbent in this position is primarily responsible for working with disabled individuals to provide work adjustment training services. The individual must be able to identify appropriate/ inappropriate work behavior by observing, using existing records, DARS data, and or feedback from family members; train consumer on various job duties, workplace policies and procedures/social skills/safe and efficient operation of equipment. Education/Experience: High School Diploma or GED and a Bachelor's degree in a related field, e.g., Education, Sociology, Social Services, or Liberal Arts and one year of full-time experience performing rehabilitation or adjustment; or an AA degree in a related field and 2 years of training/experience; possess computer skills (Microsoft Office Suite, Excel/Outlook). Goodwill Industries of East Texas in Tyler is looking for a WAT Trainer. Apply Here Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. About Phathom Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at and follow on LinkedIn and StatementsThis press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Phathom's commercialization plans. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom's business, including, without limitation: the timing of the correction to the Orange Book; the expected duration of patent term extension for VOQUEZNA; we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom's ability to obtain and maintain intellectual property protection, including patent term extensions, and non-patent regulatory exclusivity for vonoprazan; Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets; Phathom's ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. MEDIA CONTACTNick Benedetto1-877-742-8466media@ INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@ © 2025 Phathom Pharmaceuticals. All rights VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
